Literature DB >> 23074471

Deep brain stimulation for Parkinson's disease and other movement disorders: an evidence-based analysis.

.   

Abstract

OBJECTIVE: To determine the effectiveness and adverse effects of deep brain stimulation (DBS) in the treatment of symptoms of idiopathic Parkinson's disease, essential tremor, and primary dystonia and to do an economic analysis if evidence for effectiveness is established. THE TECHNOLOGY: Deep brain stimulation (DBS) is a surgical procedure indicated in the relief of motor function symptoms of Parkinson's disease, essential tremor and dystonia. It involves the surgical implantation of the DBS device, which include the implantable pulse generator or stimulator, the extension, and the lead. The electric impulse is produced within the stimulator component, and transmitted to the brain site by the extension and the lead(s). DBS surgery can be either unilateral or bilateral. The laterality of the surgery and target area for brain stimulation may vary with the type of symptom or spectrum of symptoms, and such decisions are made on a case-by-case basis. Advantages of DBS over ablative surgery is that it is comparatively less invasive, it is reversible, and it allows for stimulation of both sides of the brain. Ablative surgery, which is not practiced in Ontario, results in a non-reversible lesion and is often not conducted on both sides. Thus far, DBS has been considered as an adjunct to drug therapy. REVIEW STRATEGY: The standard Medical Advisory Secretariat search strategy was conducted to identify international health technology assessments and English language journal articles published from January 1, 2001 onwards. Documents were reviewed separately for Parkinson's disease, essential tremor and primary dystonia. SUMMARY OF
FINDINGS: There is level 1b evidence that bilateral DBS of the subthalamic nucleus is effective in the short-term control of advanced parkinsonian symptoms, and there is level 3a evidence that the effect is sustained for at least 5 years. There is Level 3a evidence that DBS of the thalamus is effective in the control of tremor in patients with essential tremor and PD for at least 6 years. There is level 3a evidence that bilateral DBS of the globus pallidus is effective in the control of symptoms of primary dystonia for at least 1 year.
CONCLUSION: According to the estimates of prevalence and evidence of effectiveness, there is a shortfall in the numbers of DBS currently done in Ontario for drug-resistant PD, essential tremor, and primary dystonia.Since complication rates are lower if DBS is performed in specialized centres, the number of sites should be limited.The cost per procedure to institutions with the expertise to undertake DBS and the human resource considerations are likely to be limiting factors in the further diffusion of DBS.

Entities:  

Year:  2005        PMID: 23074471      PMCID: PMC3382386     

Source DB:  PubMed          Journal:  Ont Health Technol Assess Ser        ISSN: 1915-7398


  35 in total

1.  Bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN) or the globus pallidus interna (GPi) for treatment of advanced Parkinson's disease.

Authors: 
Journal:  Tecnologica MAP Suppl       Date:  2001-12-06

2.  Efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson's disease 4 years after surgery: double blind and open label evaluation.

Authors:  M C Rodriguez-Oroz; I Zamarbide; J Guridi; M R Palmero; J A Obeso
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-10       Impact factor: 10.154

3.  Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia.

Authors:  Marie Vidailhet; Laurent Vercueil; Jean-Luc Houeto; Pierre Krystkowiak; Alim-Louis Benabid; Philippe Cornu; Christelle Lagrange; Sophie Tézenas du Montcel; Didier Dormont; Sylvie Grand; Serge Blond; Olivier Detante; Bernard Pillon; Claire Ardouin; Yves Agid; Alain Destée; Pierre Pollak
Journal:  N Engl J Med       Date:  2005-02-03       Impact factor: 91.245

4.  Bilateral subthalamic stimulation monotherapy in advanced Parkinson's disease: long-term follow-up of patients.

Authors:  Francesc Valldeoriola; Manuela Pilleri; Eduardo Tolosa; José L Molinuevo; Jordi Rumià; Enric Ferrer
Journal:  Mov Disord       Date:  2002-01       Impact factor: 10.338

5.  Epidemiology of focal and generalized dystonia in Rochester, Minnesota.

Authors:  J G Nutt; M D Muenter; A Aronson; L T Kurland; L J Melton
Journal:  Mov Disord       Date:  1988       Impact factor: 10.338

Review 6.  Deep brain stimulation surgery for Parkinson's disease: mechanisms and consequences.

Authors:  Andres M Lozano; Neil Mahant
Journal:  Parkinsonism Relat Disord       Date:  2004-05       Impact factor: 4.891

7.  Estimating the costs of surgical innovations: the case for subthalamic nucleus stimulation in the treatment of advanced Parkinson's disease.

Authors:  Emma McIntosh; Alastair Gray; Tipu Aziz
Journal:  Mov Disord       Date:  2003-09       Impact factor: 10.338

8.  Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: long-term follow-up.

Authors:  A Tavella; B Bergamasco; E Bosticco; M Lanotte; P Perozzo; M Rizzone; E Torre; L Lopiano
Journal:  Neurol Sci       Date:  2002-09       Impact factor: 3.307

9.  Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson's disease and motor fluctuations.

Authors:  Karen Østergaard; Niels Sunde; Erik Dupont
Journal:  Mov Disord       Date:  2002-07       Impact factor: 10.338

10.  Bilateral high frequency subthalamic stimulation in Parkinson's disease: long-term neurological follow-up.

Authors:  L M Romito; M Scerrati; M F Contarino; M Iacoangeli; A R Bentivoglio; A Albanese
Journal:  J Neurosurg Sci       Date:  2003-09       Impact factor: 2.279

View more
  3 in total

Review 1.  Magnetic Resonance-Guided Focused Ultrasound Neurosurgery for Essential Tremor: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2018-05-03

Review 2.  Perspective on the Road toward Gene Therapy for Parkinson's Disease.

Authors:  Bas Blits; Harald Petry
Journal:  Front Neuroanat       Date:  2017-01-09       Impact factor: 3.856

3.  Proteomics and bioinformatics approaches for the identification of plasma biomarkers to detect Parkinson's disease.

Authors:  Wenwen Dong; Chang Qiu; Dawei Gong; Xu Jiang; Wan Liu; Weiguo Liu; Li Zhang; Wenbin Zhang
Journal:  Exp Ther Med       Date:  2019-08-14       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.